NCT02361242View on ClinicalTrials.gov

24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Alzheimer Disease
Interventions
DRUG

PXT00864

PXT00864 is a fixed-dose combination of baclofen and acamprosate

Trial Locations (1)

Unknown

CMRR, Bordeaux

All Listed Sponsors
collaborator

Ascopharm Groupe Novasco

OTHER

lead

Pharnext S.C.A.

OTHER

NCT02361242 - 24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion | Biotech Hunter | Biotech Hunter